Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

NCT06022003 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

AML, Adult
Refractory AML
Relapsed Adult AML
FLT3-TKD Mutation
FLT3-ITD

Interventions

DRUG: AzaCITIDine Oral Tablet
DRUG: Xospata

Sponsor

French Innovative Leukemia Organisation

Collaborators

[object Object]